Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+3.10%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-05-29 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
30
May
Otsuka Holdings Co.,Ltd. JP3188220002
2026-05-29 Otsuka Holdings Co.,Ltd. “Centanafazine, a novel attention-deficit/hyperactivity disorder (ADHD) treatment with a new mechanism of action, was presented at the American Society of Clinical Psychopharmacology (ASCP) annual meeting with post-hoc analysis results from a Phase 3 trial demonstrating improvements in executive function and emotional regulation in adults with ADHD.”
30
May
Shionogi & Co.,Ltd. JP3347200002
2026-05-29 Shionogi & Co.,Ltd. “Regarding the approval of naldemedine, a treatment for opioid-induced constipation, as a new drug in China.”
30
May
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-05-29 Sumitomo Pharma Co.,Ltd. “The "Notice of Convocation of the 206th Ordinary General Meeting of Shareholders" is posted.”
30
May
Astellas Pharma Inc. JP3942400007
2026-05-29 Astellas Pharma Inc. “Notice of resignation of outside director and partial withdrawal of proposals submitted to the 21st Ordinary General Meeting of Shareholders.”
27
May
Eisai Co.,Ltd. JP3160400002
2026-05-26 Eisai Co.,Ltd. “Mitsubishi UFJ Trust and Banking Corporation and Eisai are collaborating to strengthen financial services for the elderly through the provision of information on cognitive function.”
27
May
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-05-26 CHUGAI PHARMACEUTICAL CO.,LTD. “Chugai Pharmaceutical receives the "Imperial Invention Award," the highest honor at the 2026 National Invention Awards, for its recycling antibody technology, which has been recognized for its contribution to pharmaceutical research.”
27
May
Shionogi & Co.,Ltd. JP3347200002
2026-05-26 Shionogi & Co.,Ltd. “We have posted the "Notice of Convocation of the 161st Ordinary General Meeting of Shareholders."”
27
May
Shionogi & Co.,Ltd. JP3347200002
2026-05-26 Shionogi & Co.,Ltd. “We have posted a notice of partial correction to the Notice of Convocation of the 161st Ordinary General Meeting of Shareholders.”
27
May
Astellas Pharma Inc. JP3942400007
2026-05-26 Astellas Pharma Inc. “Business Plan 2026.”
26
May
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-05-25 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approval of trastuzumab deruxtecan (T-DXd/DS-8201) for multiple HER2-positive solid tumors (260.5KB) will open in a new window.”
26
May
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-05-25 DAIICHI SANKYO COMPANY,LIMITED “The PDF file (311.8KB) regarding the partial amendment approval of Datroway® (datopotamab deruxtecan) for the first-line treatment of triple-negative breast cancer in the United States will open in a new window.”
26
May
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-05-25 CHUGAI PHARMACEUTICAL CO.,LTD. “Organizational changes and personnel announcements.”
23
May
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-05-22 Sumitomo Pharma Co.,Ltd. “Notice Regarding the Results of the Third-Party Allotment of Shares (Not Implemented).”
23
May
Astellas Pharma Inc. JP3942400007
2026-05-22 Astellas Pharma Inc. “The European CHMP has adopted a recommendation for marketing authorization of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab for cisplatin-unsuitable resectable muscle-invasive bladder cancer.”
22
May
Eisai Co.,Ltd. JP3160400002
2026-05-21 Eisai Co.,Ltd. “At the American Society of Clinical Oncology (ASCO) Annual Meeting, we presented new data that reinforces the clinical evidence for the approved indications of Lenvima® (lenvatinib).”
20
May
Shionogi & Co.,Ltd. JP3347200002
2026-05-19 Shionogi & Co.,Ltd. “Regarding the positive interim analysis results of the domestic Phase III clinical trial of the aromatic hydrocarbon receptor (AhR) modulator "Tapinarov Cream 0.5%" in infants and young children with atopic dermatitis.”
20
May
Astellas Pharma Inc. JP3942400007
2026-05-19 Astellas Pharma Inc. “At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, we will present data on the long-term outcomes and real-world clinical use of our portfolio across all disease stages.”
20
May
Takeda Pharmaceutical Company Limited JP3463000004
2026-05-19 Takeda Pharmaceutical Company Limited “Regarding the jury verdict in the U.S. antitrust lawsuit concerning AMITIZA® (lubiprostone) and the related revision of the financial results for the fiscal year ending March 2026 (FY2025).”
19
May
Otsuka Holdings Co.,Ltd. JP3188220002
2026-05-18 Otsuka Holdings Co.,Ltd. “FACEDUO launches new program "Heatstroke Prevention VR" to allow users to experience the signs of heatstroke and take action to prevent it from occurring or becoming severe in the elderly.”
19
May
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-05-18 DAIICHI SANKYO COMPANY,LIMITED “The PDF file (277.7KB) regarding the approval of two partial changes to the Enhertu® (trastuzumab deruxtecan) drug for HER2-positive early-stage breast cancer in the United States will open in a new window.”